ENG and neoplasm: Nanographenes synthesized to target CD105 with anti-CD105 mAb or microbubbles conjugated with anti-vascular endothelial growth factor (VEGF) mAb have been reported to be specifically directed to tumor microvasculature in vivo [15, 16].